SK391891A3 - Xanthine derivatives and pharmaceutical composition comprising same - Google Patents
Xanthine derivatives and pharmaceutical composition comprising same Download PDFInfo
- Publication number
- SK391891A3 SK391891A3 SK3918-91A SK391891A SK391891A3 SK 391891 A3 SK391891 A3 SK 391891A3 SK 391891 A SK391891 A SK 391891A SK 391891 A3 SK391891 A3 SK 391891A3
- Authority
- SK
- Slovakia
- Prior art keywords
- formula
- dicyclopropylmethyl
- group
- compound
- xanthine derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB898906792A GB8906792D0 (en) | 1989-03-23 | 1989-03-23 | Treatment and compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
SK391891A3 true SK391891A3 (en) | 2000-12-11 |
Family
ID=10653940
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK3918-91A SK391891A3 (en) | 1989-03-23 | 1991-12-19 | Xanthine derivatives and pharmaceutical composition comprising same |
Country Status (27)
Country | Link |
---|---|
US (4) | US5734051A (hu) |
EP (2) | EP0389282B1 (hu) |
JP (1) | JP2510889B2 (hu) |
KR (1) | KR0160768B1 (hu) |
CN (1) | CN1031641C (hu) |
AT (1) | ATE213498T1 (hu) |
AU (1) | AU629315B2 (hu) |
CA (1) | CA2012686C (hu) |
CZ (1) | CZ391891A3 (hu) |
DE (1) | DE69033915T2 (hu) |
DK (1) | DK0389282T3 (hu) |
ES (1) | ES2173074T3 (hu) |
FI (1) | FI95033C (hu) |
GB (1) | GB8906792D0 (hu) |
HK (1) | HK1040392A1 (hu) |
HU (1) | HU207081B (hu) |
IL (1) | IL93832A (hu) |
MA (1) | MA21800A1 (hu) |
MY (1) | MY109737A (hu) |
NO (1) | NO175592C (hu) |
NZ (1) | NZ233021A (hu) |
PL (1) | PL164811B1 (hu) |
PT (1) | PT93527B (hu) |
SA (1) | SA90100215B1 (hu) |
SK (1) | SK391891A3 (hu) |
ZA (1) | ZA902170B (hu) |
ZW (1) | ZW3690A1 (hu) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5021422A (en) * | 1989-06-08 | 1991-06-04 | Senetek Plc | Method and composition for treating hyperproliferative skin diseases using 6-aminopurine cytokinins |
GB9020921D0 (en) * | 1990-09-26 | 1990-11-07 | Beecham Group Plc | Novel compounds |
GB9020959D0 (en) * | 1990-09-26 | 1990-11-07 | Beecham Group Plc | Novel compounds |
IL100088A (en) * | 1990-11-21 | 1995-07-31 | Smithkline Beecham Corp | FNT inhibitor preparations containing histogenic transducts converted at positions 1, 3, and 8 |
ATE194345T1 (de) * | 1990-12-21 | 2000-07-15 | Beecham Group Plc | Xanthinderivate |
ATE141791T1 (de) | 1991-07-05 | 1996-09-15 | Byk Gulden Lomberg Chem Fab | Verwendung substituierter pyridazine gegen dermatosen |
WO1993016699A1 (en) * | 1992-02-21 | 1993-09-02 | Smithkline Beecham Corporation | Tnf inhibitors |
US5342841A (en) * | 1992-03-12 | 1994-08-30 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivatives |
CA2093403C (en) * | 1992-04-08 | 1999-08-10 | Fumio Suzuki | Therapeutic agent for parkinson's disease |
GB9210839D0 (en) * | 1992-05-21 | 1992-07-08 | Smithkline Beecham Plc | Novel compounds |
GB9215633D0 (en) * | 1992-07-23 | 1992-09-09 | Smithkline Beecham Plc | Novel treatment |
US6469017B1 (en) | 1998-01-16 | 2002-10-22 | Cell Therapeutics, Inc. | Method of inhibiting interleukin-12 signaling |
US6693105B1 (en) | 1992-11-16 | 2004-02-17 | Cell Therapeutics, Inc. | Hydroxyl-containing compounds |
GB9312853D0 (en) | 1993-06-22 | 1993-08-04 | Euro Celtique Sa | Chemical compounds |
US6878715B1 (en) * | 1994-02-18 | 2005-04-12 | Cell Therapeutics, Inc. | Therapeutic compounds for inhibiting interleukin-12 signals and method for using same |
US5646156A (en) * | 1994-04-25 | 1997-07-08 | Merck & Co., Inc. | Inhibition of eosinophil activation through A3 adenosine receptor antagonism |
US5922751A (en) | 1994-06-24 | 1999-07-13 | Euro-Celtique, S.A. | Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same |
US5591776A (en) | 1994-06-24 | 1997-01-07 | Euro-Celtique, S.A. | Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV |
EP0799040B1 (en) | 1994-12-13 | 2003-08-20 | Euroceltique S.A. | Trisubstituted thioxanthines |
CA2206287C (en) * | 1994-12-13 | 2001-03-20 | Mark Chasin | Aryl thioxanthines |
EP0825993A1 (en) * | 1995-05-19 | 1998-03-04 | Chiroscience Limited | Xanthines and their therapeutic use |
US6166041A (en) | 1995-10-11 | 2000-12-26 | Euro-Celtique, S.A. | 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma |
US6075016A (en) | 1996-04-10 | 2000-06-13 | Euro-Celtique S.A. | 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity |
US5864037A (en) | 1996-06-06 | 1999-01-26 | Euro-Celtique, S.A. | Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity |
US5958926A (en) * | 1996-11-01 | 1999-09-28 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
GB9623859D0 (en) * | 1996-11-15 | 1997-01-08 | Chiroscience Ltd | Novel compounds |
GB9703044D0 (en) | 1997-02-14 | 1997-04-02 | Glaxo Group Ltd | Phenyl xanthine esters and amides |
ATE325610T1 (de) * | 1997-09-05 | 2006-06-15 | Kyowa Hakko Kogyo Kk | Xanthinderivative zur behandlung von hirnischämie |
MA24682A1 (fr) | 1997-10-23 | 1999-07-01 | Smithkline Beecham Corp | Formes polymorphes nouvelles de cipamfylline, procede pour leur preparation et compositions les contenant |
GB9817623D0 (en) | 1998-08-13 | 1998-10-07 | Glaxo Group Ltd | Pharmaceutical compounds |
CA2381802C (en) | 1999-08-21 | 2010-12-07 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Synergistic combination of roflumilast and salmeterol |
WO2001068600A2 (en) * | 2000-03-16 | 2001-09-20 | Inflazyme Pharmaceuticals Limited | Benzylated pde4 inhibitors |
US6821978B2 (en) * | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
US6586429B2 (en) * | 2000-11-29 | 2003-07-01 | Cell Therapeutics, Inc. | Tricyclic fused xanthine compounds and their uses |
KR100926247B1 (ko) * | 2001-02-24 | 2009-11-12 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 크산틴 유도체를 포함하는 약제학적 조성물 및 이의제조방법 |
DE60228073D1 (de) * | 2001-05-08 | 2008-09-18 | Brni Neurosciences Inst | Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen |
US6825180B2 (en) * | 2001-05-18 | 2004-11-30 | Cell Therapeutics, Inc. | Pyridopyrimidine compounds and their uses |
AU2002333193A1 (en) * | 2001-08-15 | 2003-03-03 | Leo Pharma A/S | A pharmaceutical composition for dermal application |
DE60226615D1 (hu) | 2001-08-28 | 2008-06-26 | Schering Corp | |
WO2003042216A1 (en) | 2001-11-09 | 2003-05-22 | Schering Corporation | Polycyclic guanine derivative phosphodiesterase v inhibitors |
US20030175314A1 (en) * | 2001-11-19 | 2003-09-18 | Didriksen Erik Johannes | Pharmaceutical composition for dermal application |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
EA200501548A1 (ru) | 2003-04-01 | 2006-02-24 | Апплайд Резеч Системз Арс Холдинг Н.В. | Ингибиторы фосфодиэстераз при бесплодии |
MXPA06001195A (es) * | 2003-07-31 | 2006-04-11 | Schering Corp | Metabolito de inhibidor de xantina fosfodiesterasa 5 y derivados del mismo utiles para el tratamiento de la disfuncion erectil. |
BRPI0417241A (pt) * | 2003-12-09 | 2007-03-06 | Kyowa Hakko Kogyo Kk | agente e processo para a prevenção e/ou para o tratamento de disfunção do cérebro superior, e, uso de um derivado de xantina, ou um sal farmaceuticamente aceitável do mesmo |
NZ548496A (en) * | 2004-02-14 | 2010-02-26 | Smithkline Beecham Corp | Medicaments with HM74A receptor activity for disorder of lipid metabolism |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
DE102004030502A1 (de) | 2004-06-24 | 2006-01-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
ATE487719T1 (de) | 2005-08-10 | 2010-11-15 | Glaxosmithkline Llc | Xanthinderivate als selektive hm74a-agonisten |
KR20080100264A (ko) * | 2006-03-21 | 2008-11-14 | 닥터 레디스 레보러터리즈 리미티드 | 도세탁셀의 다형체와 그 제조방법 |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
NZ573360A (en) | 2006-05-04 | 2012-08-31 | Boehringer Ingelheim Int | Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine |
WO2008017670A1 (en) | 2006-08-08 | 2008-02-14 | Boehringer Ingelheim International Gmbh | Pyrrolo [3, 2 -d] pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus |
EP2170930B3 (en) | 2007-06-04 | 2013-10-02 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
US8871751B2 (en) * | 2008-01-18 | 2014-10-28 | The Board Of Trustees Of The University Of Illinois | Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer |
AR071175A1 (es) | 2008-04-03 | 2010-06-02 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante |
JP2011522828A (ja) | 2008-06-04 | 2011-08-04 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
AU2009270833B2 (en) | 2008-07-16 | 2015-02-19 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
JP2012502081A (ja) | 2008-09-10 | 2012-01-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病及び関連症状の治療のための組み合わせ治療 |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
TWI508965B (zh) | 2008-12-23 | 2015-11-21 | Boehringer Ingelheim Int | 有機化合物的鹽形式 |
TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
JP2013512229A (ja) | 2009-11-27 | 2013-04-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 遺伝子型が同定された糖尿病患者のリナグリプチン等のddp−iv阻害薬による治療 |
NZ602921A (en) | 2010-05-05 | 2016-01-29 | Boehringer Ingelheim Int | Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor |
MX2012014247A (es) | 2010-06-24 | 2013-01-18 | Boehringer Ingelheim Int | Terapia para la diabetes. |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
DK2681236T3 (en) | 2011-03-01 | 2018-04-16 | Synergy Pharmaceuticals Inc | PROCEDURE FOR MANUFACTURING GUANYLATE CYCLASE-C-AGONISTS |
EP3517539B1 (en) | 2011-07-15 | 2022-12-14 | Boehringer Ingelheim International GmbH | Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
EP2958577A2 (en) | 2013-02-25 | 2015-12-30 | Synergy Pharmaceuticals Inc. | Guanylate cyclase receptor agonists for use in colonic cleansing |
CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
EP3004138B1 (en) | 2013-06-05 | 2024-03-13 | Bausch Health Ireland Limited | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
AU2014305843B2 (en) | 2013-08-09 | 2019-08-29 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
PT3251675T (pt) | 2015-01-30 | 2021-05-25 | Shanton Pharma Pte Ltd | Prevenção ou tratamento de doença de ácido úrico ou gota |
JP6738405B2 (ja) | 2015-04-08 | 2020-08-12 | ルイス アンド クラーク ファーマシューティカルズ、インコーポレイテッド | A2b拮抗薬としてのキサンチン置換アルキニルカルバメート/逆カルバメート |
EP3165224A1 (en) | 2015-11-09 | 2017-05-10 | Albert-Ludwigs-Universität Freiburg | Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders |
WO2017089347A1 (en) | 2015-11-25 | 2017-06-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas |
EP3468562A1 (en) | 2016-06-10 | 2019-04-17 | Boehringer Ingelheim International GmbH | Combinations of linagliptin and metformin |
US20200368223A1 (en) | 2019-05-21 | 2020-11-26 | Ardelyx, Inc. | Methods for inhibiting phosphate transport |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US757328A (en) * | 1903-02-07 | 1904-04-12 | Boehringer & Soehne | Art of preparing xanthin derivatives. |
US2517410A (en) * | 1947-08-15 | 1950-08-01 | Searle & Co | Hydroxy alkyl xanthines and the production thereof |
US2534813A (en) * | 1950-01-21 | 1950-12-19 | Searle & Co | 8-haloxanthine salts of cyclic-aminoalkyl benzohydryl ethers and the production thereof |
US4120947A (en) * | 1976-03-31 | 1978-10-17 | Cooper Laboratories, Inc. | Xanthine compounds and method of treating bronchospastic and allergic diseases |
CH654008A5 (fr) * | 1979-05-22 | 1986-01-31 | Nestle Sa | Procede de preparation de 1,3,7-trialkylxanthines. |
IT1200944B (it) * | 1982-08-10 | 1989-01-27 | Malesci Sas | Derivati xantinici,procedimento per la loro preparazione,composizione farmaceutiche che il contengono e loro impiego terapeutico |
US4593095A (en) * | 1983-02-18 | 1986-06-03 | The Johns Hopkins University | Xanthine derivatives |
US4567183A (en) * | 1983-03-11 | 1986-01-28 | Analgesic Associates | Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same |
US4558051A (en) * | 1983-10-11 | 1985-12-10 | Richardson-Vicks, Inc. | Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same |
DE3406533A1 (de) * | 1984-02-23 | 1985-08-29 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten |
US4666914A (en) * | 1985-05-13 | 1987-05-19 | Schering Corporation | Anti-inflammatory and anti-allergic substituted-2,3-dihydro-6-(hydroxy)pyrimido[2,1-f]-purine-4,8(1H,9H)-diones |
GB8610136D0 (en) * | 1986-04-25 | 1986-05-29 | Wellcome Found | Compounds |
GB8621869D0 (en) * | 1986-09-11 | 1986-10-15 | Beecham Group Plc | Treatment |
DK674487A (da) | 1986-12-22 | 1988-06-23 | Zambeletti Spa L | Piperidinderivater |
IT1197516B (it) * | 1986-12-24 | 1988-11-30 | Abc Ist Biolog Chem Spa | Derivati teofillinmetilanici e teofillinmetilditianici procedimento per la loro preparazione e composizioni farmaceutiche che li comprendono |
-
1989
- 1989-03-23 GB GB898906792A patent/GB8906792D0/en active Pending
-
1990
- 1990-03-20 MA MA22044A patent/MA21800A1/fr unknown
- 1990-03-21 AU AU52083/90A patent/AU629315B2/en not_active Ceased
- 1990-03-21 NO NO901300A patent/NO175592C/no unknown
- 1990-03-21 ZA ZA902170A patent/ZA902170B/xx unknown
- 1990-03-21 CA CA002012686A patent/CA2012686C/en not_active Expired - Fee Related
- 1990-03-21 PT PT93527A patent/PT93527B/pt not_active IP Right Cessation
- 1990-03-21 NZ NZ233021A patent/NZ233021A/en unknown
- 1990-03-21 IL IL9383290A patent/IL93832A/en unknown
- 1990-03-22 ZW ZW36/90A patent/ZW3690A1/xx unknown
- 1990-03-22 AT AT90303093T patent/ATE213498T1/de not_active IP Right Cessation
- 1990-03-22 KR KR1019900003902A patent/KR0160768B1/ko not_active IP Right Cessation
- 1990-03-22 EP EP90303093A patent/EP0389282B1/en not_active Expired - Lifetime
- 1990-03-22 HU HU901792A patent/HU207081B/hu not_active IP Right Cessation
- 1990-03-22 ES ES90303093T patent/ES2173074T3/es not_active Expired - Lifetime
- 1990-03-22 FI FI901447A patent/FI95033C/fi not_active IP Right Cessation
- 1990-03-22 EP EP00203905A patent/EP1120417A3/en not_active Withdrawn
- 1990-03-22 DK DK90303093T patent/DK0389282T3/da active
- 1990-03-22 DE DE69033915T patent/DE69033915T2/de not_active Expired - Fee Related
- 1990-03-23 PL PL90284429A patent/PL164811B1/pl not_active IP Right Cessation
- 1990-03-23 MY MYPI90000465A patent/MY109737A/en unknown
- 1990-03-23 JP JP2075359A patent/JP2510889B2/ja not_active Expired - Fee Related
- 1990-03-23 CN CN90102240A patent/CN1031641C/zh not_active Expired - Fee Related
- 1990-05-08 SA SA90100215A patent/SA90100215B1/ar unknown
-
1991
- 1991-12-19 SK SK3918-91A patent/SK391891A3/sk unknown
- 1991-12-19 CZ CS913918A patent/CZ391891A3/cs unknown
-
1995
- 1995-06-07 US US08/477,157 patent/US5734051A/en not_active Expired - Fee Related
- 1995-06-07 US US08/474,093 patent/US5981535A/en not_active Expired - Fee Related
-
1998
- 1998-02-17 US US09/024,252 patent/US6180791B1/en not_active Expired - Fee Related
- 1998-12-15 HK HK02100617.1A patent/HK1040392A1/zh unknown
-
2000
- 2000-11-08 US US09/708,338 patent/US6531600B1/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SK391891A3 (en) | Xanthine derivatives and pharmaceutical composition comprising same | |
US4294831A (en) | Purine derivatives | |
US4199574A (en) | Methods and compositions for treating viral infections and guanine acyclic nucleosides | |
US4146715A (en) | 2-amido-9-(2-acyloxyethoxymethyl)hypoxanthines | |
JPH09501918A (ja) | 酸化窒素合成酵素活性を有するアミジン誘導体 | |
PL158285B1 (en) | Method of obtaining novel derivatives of 9-(2-hydroxyetoxymethyl-guanine | |
US4120947A (en) | Xanthine compounds and method of treating bronchospastic and allergic diseases | |
EP0369744B1 (en) | Xanthine derivatives, process for their preparation and pharmaceutical compositions | |
JPS63297381A (ja) | 9−〔2−(ヒドロキシメチル)シクロアルキルメチル〕グアニン類 | |
KR940010033B1 (ko) | 항비루스 활성을 갖는 화합물의 제조방법 | |
US4060616A (en) | Purine derivatives with repeating unit | |
EP0366385A1 (en) | Guanine derivatives having antiviral activity and their pharmaceutically acceptable salts | |
EP0531349A1 (en) | 1-7 substituted xanthine derivatives having antiasthmatic activity, their salts physiologically acceptable, pharmaceutical composition containing them and process for their preparation | |
WO1998002166A1 (en) | Adenosine deaminase inhibitors | |
DE69531555T2 (de) | Dreifachsubstituierte thioxanthine | |
IE44708B1 (en) | Esters of hydroxyalkoxylkyl purines, their preparation, and pharmaceutical compositions containing them | |
CS203095B2 (cs) | Způsob přípravy substituovaných purinů | |
JPH06206880A (ja) | 新規シクロペンテン誘導体 |